Organovo Holdings, Inc., has announced the publication of data in Frontiers in Physiology showing the company’s 3D bioprinted proximal tubule tissue model exhibits key characteristics of renal physiology that allow for in vitro kidney toxicity testing.
According to Dr. Sharon Presnell, chief scientic officer, Organovo, most traditional preclinical models often fall short in their ability to inform clinical outcomes accurately, largely due to the limited functionality of simple in vitro models and species differences. The Organovo’s 3D bioprinted human kidney tissue has great potential to assess the toxic effects of compounds and the development and progression of complex, multicellular processes such as fibrosis.”
The article, written by scientific executives and experts from the FDA, Merck & Co., Inc and LifeNet Health, provides a thorough review of human tissue models and how they can accelerate drug development across all discovery stages, including Organovo’s 3D bioprinted liver model.
The article authors reference Organovo’s technology as a innovation in the study of drug-induced liver injury. They stated that 3D bioprinted tissues exhibit a broad range of highly differentiated in vivo like features and functions.
The authors reference results from Organovo’s drug-induced liver injury studies that have shown very good reproducibility and concordance with observed outcomes in vivo at the functional and histological levels and that treatment of the bioprinted human liver model with known fibrotic agents mimicked closely that of patient liver samples with drug-induced fibrosis.